文献速递自身炎症与 IgG4 相关病

沙利度胺可有效预防IgG4相关性疾病复发且获益大于副作用:一项多中心、随机、双盲、安慰剂对照研究

Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study.
PubMed 文献 · Ann Rheum Dis · 2025-02-16

该多中心随机双盲安慰剂对照研究纳入60例活动期IgG4相关性疾病患者,随机分为糖皮质激素+沙利度胺组与糖皮质激素+安慰剂组,按方案完成57例。第12个月沙利度胺组复发率13.8%低于安慰剂组67.8%,缓解率75.8%高于安慰剂组32.1%,基于复发和中度不良事件的获益-风险分析显示沙利度胺治疗的需治疗人数为2、需伤害人数为8。

要点

  • 第12个月复发率:糖皮质激素+沙利度胺组13.8% vs 糖皮质激素+安慰剂组67.8%。
  • 第12个月缓解率:糖皮质激素+沙利度胺组75.8% vs 糖皮质激素+安慰剂组32.1%。
  • 基于复发和中度不良事件的需治疗人数为2、需伤害人数为8。

核心结论

  • 沙利度胺可有效预防IgG4相关性疾病复发,且获益大于副作用,提示沙利度胺可作为IgG4相关性疾病预防复发并减少激素使用的潜在安全治疗选择。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照研究,纳入疾病活动状态的合格患者,按1:1比例随机分为2组(第1组:糖皮质激素+沙利度胺;第2组:糖皮质激素+安慰剂)。
  • 共60例患者被随机分组,57例(糖皮质激素+沙利度胺组29例;糖皮质激素+安慰剂组28例)按方案完成研究。

主要发现

  • 第12个月复发率:糖皮质激素+沙利度胺组13.8% vs 糖皮质激素+安慰剂组67.8%。
  • 两组均观察到100%的应答率;第12个月缓解率:糖皮质激素+沙利度胺组75.8% vs 糖皮质激素+安慰剂组32.1%。
  • 共35例参与者记录49例不良事件,其中4例为中度,45例为轻度。
  • 基于12个月随访期内疾病复发率和中度不良事件评估的获益-风险分析显示,沙利度胺治疗的需治疗人数(NNT)为2,需伤害人数(NNH)为8。

关键数值与推荐

  • 主要结局为第12个月疾病复发率;次要结局为第12个月疾病缓解率和不良事件发生率。
  • 第12个月复发率:糖皮质激素+沙利度胺组13.8% vs 糖皮质激素+安慰剂组67.8%。
  • 第12个月缓解率:糖皮质激素+沙利度胺组75.8% vs 糖皮质激素+安慰剂组32.1%。
  • 基于12个月随访期内疾病复发率和中度不良事件评估的获益-风险分析:沙利度胺治疗的NNT为2,NNH为8。

临床怎么用

  • 原文结论指出沙利度胺可有效预防IgG4相关性疾病复发且获益大于副作用,提示其可作为IgG4相关性疾病预防复发并减少激素使用的潜在安全治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the effects of thalidomide in preventing disease relapse with 'zero' glucocorticoids (GCs) usage in IgG4-related disease (IgG4-RD). METHODS: This was a multicentre, randomised, double-blinded, placebo-controlled study, in which eligible patients in disease active status were randomised into 2 groups (group 1: GCs+Thalidomide; group 2: GCs+Placebo) at a 1:1 ratio. The primary outcome of this trial was the disease relapse rate at month 12, whereas the secondary outcomes were the disease remission rate at month 12 and the incidence of adverse events (AEs). RESULTS: A total of 60 patients were randomised, and 57 patients (GCs+Thalidomide: 29; GCs+Placebo: 28) finished the study per protocol. The relapse rates of the GCs+Thalidomide and GCs+Placebo groups at month 12 were 13.8% and 67.8%, respectively. A 100% response rate was observed in both treatment group, while the remission rates of the GCs+Thalidomide and GCs+Placebo groups were 75.8% and 32.1%, respectively. In total. 49 AEs were recorded in 35 participants, in which 4 were graded as moderate, and 45 were graded as mild. The risk-benefit analysis based on the evaluation of rates of disease relapse and moderate AEs within the 12-month follow-up showed a NNT (number needed to treat) of 2 and a NNH (number needed to harm) of 8 for thalidomide treatment. CONCLUSIONS: Thalidomide can effectively prevent relapse in IgG4-RD outweighing its side effects, which indicating that thalidomide can be a potential safe therapeutic option for disease relapse prevention in parallel with steroid sparing in IgG4-RD.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Chen Y, Ye C, Yang P, et al. Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study. Ann Rheum Dis. 2025. PMID: 39956699. doi:10.1016/j.ard.2025.01.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。